Drug intelligence / Profile preview

YDC101

Development stage: Preclinical
Lead developer: YD Global Life Science
Modality: Small Molecules

Overview

YDC101 is a small molecule drug candidate being developed by YD Global Life Science in collaboration with SapiensBio. The active ingredient in YDC101 is imatinib mesylate, a well-characterized tyrosine kinase inhibitor. YDC101 specifically targets the c-Kit receptor (also known as CD117 or Mast/stem cell growth factor receptor Kit), which plays a significant role in cellular signaling pathways related to vascular permeability and cell proliferation. The drug is currently in the preclinical lead optimization stage, with primary development focuses in ophthalmology—specifically for the treatment of diabetic macular edema (DME) and diabetic retinopathy (DR)—and potential applications in oncology.

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)

Beyond the preview

Go deeper on YDC101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YDC101.

Explore the full profile